Cancer Immunochemotherapy: Preliminary Studies with Triazene Compounds
One of the most challenging problems of cancer immunotherapy in the clinic concerns the poor immune response of the host for the autochthonous tumor. This is, at least in part, due to the scarce immunogenicity of neoplastic cells, which are not recognized by host’s natural or antigen-dependent immune apparatus. In order to overcome this difficulty, the immunopharmacological approach of “Chemical Xenogenization” (CX) has been introduced by our laboratory in 1970 (1). It has been found that in vivo treatment of leukemia-bearing mice with triazene compounds (TZC) leads to the appearance of novel transplantation antigens on the membrane of neoplastic cells (2–4). TZC-treated cells are rejected by syngeneic hosts and elicit specific cytotoxic T lymphocyte (CTL) responses (1–14). The principal features of CX in mouse leukemias are summarized in Table 1.
KeywordsAcute Myelogenous Leukemia Transplantation Antigen Acute Myelogenous Leukemia Blast Liquid Hybridization Murine Lymphoma Cell
Unable to display preview. Download preview PDF.
- 6.B.Nardelli, A.R.Contessa, L.Romani, G.Sava, C.Nisi, and M.C.Fioretti, Immunogenic changes of murine lymphoma cells following in vitro treatment with aryl-triazenederivatives,Cancer Immunol. Immunother. 16:157 (1984).Google Scholar
- 13.A.Santoni, Y.Kinney, A.Goldin, Secondary cytotoxic response in vitro against Moloney lymphoma cells antigenically altered by drug-treatment in vivo, J.Natn.Cancer Inst. 60: 109 (1978).Google Scholar
- 17.L.Romani, U.Grohmann, F.Fazioli, P.Puccetti, M.G.Mage, and M.C.Fioretti, Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens, Cancer Immunol. Immunother . 26:48 (1988).Google Scholar
- 22.U.Grohmann, L.Binaglia, P.Puccetti, and M.C.Fioretti, Murine leukemia virus gp70 antisense oligonucleotides inhibit CTL-mediated lysis of a drug-treated lymphoma, 8th Int. Congr. of Immunology, Budapest, Hungary August 23–28, 1992.Google Scholar
- 25.A.E.Pegg, L.Wiest, R.S.Foote, S.Mitra, and W.Perry, Purification and properties of 06-methylguanine-DNAtransmethylase from rat liver, J.Biol.Chem. 258: 2327 (1983)Google Scholar
- 28.M.C.Fioretti, L.Romani, E.Bonmassar, Antigenic changes related to drug-action, in: “Biology of Cancer” (13th Int. Cancer Congress, Part B), E.A.Mirand, W.B.Hutchinson, and E.Mihich eds., Alan R.Liss Inc., New York (1983).Google Scholar
- 33.G.D.Ehrlich, S.Greenberg and M.Abbot, Detection of human T-cell lymphoma/leukemia viruses, in: “PCR protocol. A guide to methods and applications”, M.A.Innis, D.H.Gelfand, J.J. Sninsky, and T.J.White eds., Academic Press Inc. (1990).Google Scholar
- 35.S.Knok, G.Ehrlich, B.Poiesz. R. Kalish and J.J.Sninsky, Enzymatic amplification of HTLV-I viral sequences from peripheral blood mononuclear cells and infected tissues, Blood 72: 1117 (1988).Google Scholar
- 39.S.D’Atri, L.Tentori, M.Tricarico, and E.Bonmassar, Effects of triazenes on immune responses, in: “Triazenes. Chemical, Biological and Clinical aspects”, T.Giraldi, T.A.Connors, and G.Cartei eds., Plenum Press, New York-London (1990).Google Scholar